This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, J.
Right arrow Articles by Jenkins, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, J.
Right arrow Articles by Jenkins, S. G.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2009, p. 1611-1612, Vol. 47, No. 5
0095-1137/09/$08.00+0     doi:10.1128/JCM.02466-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Decreased Susceptibility to Polymyxin B during Treatment for Carbapenem-Resistant Klebsiella pneumoniae Infection{triangledown}


arrow
LETTER
 
In the United States, the major mechanism of carbapenem resistance among Enterobacteriaceae is the production of Klebsiella pneumoniae carbapenemase (KPC) (2). Polymyxins and tigecycline are the antimicrobials most often used for treatment of infections caused by carbapenem-resistant Enterobacteriaceae (4, 11). Polymyxin B, discovered more than 60 years ago, has been reintroduced as a valuable therapeutic agent with efficacy against multidrug-resistant gram-negative bacteria due to a shortage of new antimicrobials with activities against these organisms. While polymyxin B resistance has been observed in clinical isolates of carbapenem-resistant K. pneumoniae (CRKP), reports of developing resistance in vivo during treatment with polymyxin B are limited (1, 8).

We studied patients with CRKP infections who persistently had positive cultures despite ≥3 days of treatment with either polymyxin B alone or polymyxin B and tigecycline. The patients were hospitalized between July 2004 and June 2006 at the Mount Sinai Hospital (New York, NY). The history of antibiotic therapy and the duration of treatment were obtained from patients' medical records and hospital pharmacy records. Carbapenem resistance in K. pneumoniae isolates was initially detected by using an automated broth microdilution system (MicroScan; Dade Behring, Deerfield, IL), followed by confirmation with the disk diffusion assay and Etest (AB Biodisk, Solna, Sweden). The presence of the KPC gene in each isolate was tested by PCR analysis using primers and conditions described elsewhere (12). The MICs for polymyxin B and tigecycline were determined by Etest.

Of the 16 patients included in this study, 12 received polymyxin B (polymyxin B sulfate) alone for a mean duration of 12.6 days (range, 3 to 25 days) and 4 received both polymyxin B and tigecycline for a mean duration of 9.3 days (range, 4 to 23 days) and 9 days (range, 3 to 16 days), respectively. Polymyxin B and tigecycline were given as a combination therapy for a mean duration of 6.25 days (range, 3 to 15 days) for those who received both agents. All patients received a therapeutic dose of polymyxin B, which was renally adjusted if needed. The initial CRKP isolates were recovered from blood (12 patients), peritoneal fluid (2 patients), sputum (1 patient), and cerebrospinal fluid (1 patient) samples. All of the subsequent CRKP isolates were recovered from blood samples. The KPC gene was present in all initial and subsequent isolates as confirmed by PCR analysis. The mean time interval between the recovery of initial and subsequent isolates was 16.6 days (range, 4 to 55 days) for those who received polymyxin B alone and 15.5 days (range, 4 to 42 days) for those who received both polymyxin B and tigecycline. Significant increases in the polymyxin B MIC were observed in the subsequent isolates recovered from 3 of 12 patients (25%) treated with only polymyxin B: 1.5 µg/ml to 32 µg/ml, 0.75 µg/ml to 12 µg/ml, and 0.75 µg/ml to 1024 µg/ml, respectively (Table 1). The mean durations of treatment with polymyxin B for these three patients were not different from those for the other nine patients whose subsequent isolates did not have an increased MIC (mean, 15.7 days versus 10.8 days; P = 0.46). During the study period, more than 90% of CRKP clinical isolates at our institution demonstrated in vitro susceptibilities to polymyxin B. None of the subsequent isolates from patients who received both polymyxin B and tigecycline showed changes in the MIC for either polymyxin B or tigecycline.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Increased MIC of polymyxin B for CRKP isolates from three patients treated with polymyxin B

This observation may be explained by the emergence of resistance in the same strain or reinfection with a resistant strain from a heterogeneous bacterial population under antibiotic selective pressure. The clonal relationship between the initial and subsequent isolates was not examined in this study. The mechanisms of resistance to polymyxin in K. pneumoniae may be mediated by modification of the lipopolysaccharide of the outer membrane or by increased production of capsular polysaccharide (5, 13). These molecular changes induced by mutation are known to confer a low level of resistance and occur slowly (3, 5), in contrast to our cases in which isolates showed a significantly increased MIC in a relatively short period of time: 14 days, 21 days, and 5 days, respectively (Table 1). Reinfection with a resistant strain under antibiotic selective pressure might be implicated in these cases, and perhaps combination therapy with polymyxin B and tigecycline might have prevented this in patients who received both agents.

Although polymyxin and tigecycline do not show a synergistic effect on K. pneumoniae in vitro (10), they are not antagonistic and may have an additive effect when used together (9). Of importance is that combination therapy may prevent the emergence of resistance in CRKP isolates. Further studies are needed to determine the clinical significance of our findings and to evaluate the in vivo efficacy of combination therapy with polymyxin and tigecycline for treatment of CRKP infection.


arrow
ACKNOWLEDGMENTS
 
There was no financial support for this study.

There are no conflicts of interest.


arrow
FOOTNOTES
 
{triangledown} Published ahead of print on 4 March 2009. Back


arrow
REFERENCES
 
    1
  1. Antoniadou, A., F. Kontopidou, G. Poulakou, E. Koratzanis, I. Galani, E. Papadomichelakis, P. Kopterides, M. Souli, A. Armaganidis, and H. Giamarellou. 2007. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J. Antimicrob. Chemother. 59:786-790.[Abstract/Free Full Text]
    2. 2
  2. Castanheira, M., H. S. Sader, L. M. Deshpande, T. R. Fritsche, and R. N. Jones. 2008. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 52:570-573.[Abstract/Free Full Text]
    3. 3
  3. Falagas, M. E., and S. K. Kasiakou. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341.[CrossRef][Medline]
    4. 4
  4. Kelesidis, T., D. E. Karageorgopoulos, I. Kelesidis, and M. E. Falagas. 2008. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J. Antimicrob. Chemother. 62:895-904.[Abstract/Free Full Text]
    5. 5
  5. Li, J., R. L. Nation, R. W. Milne, J. D. Turnidge, and K. Coulthard. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25.[CrossRef][Medline]
    6. 6
  6. Reference deleted.
    7. 7
  7. Reference deleted.
    8. 8
  8. Matthaiou, D. K., A. Michalopoulos, P. I. Rafailidis, D. E. Karageorgopoulos, V. Papaioannou, G. Ntani, G. Samonis, and M. E. Falagas. 2008. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit. Care Med. 36:807-811.[Medline]
    9. 9
  9. Moland, E. S., D. W. Craft, S. G. Hong, S. Y. Kim, L. Hachmeister, S. D. Sayed, and K. S. Thomson. 2008. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. Antimicrob. Agents Chemother. 52:2940-2942.[Abstract/Free Full Text]
    10. 10
  10. Petersen, P. J., P. Labthavikul, C. H. Jones, and P. A. Bradford. 2006. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J. Antimicrob. Chemother. 57:573-576.[Abstract/Free Full Text]
    11. 11
  11. Petrosillo, N., E. Ioannidou, and M. E. Falagas. 2008. Colistin monotherapy versus combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 14:816-827.[CrossRef][Medline]
    12. 12
  12. Yigit, H., A. M. Queenan, G. J. Anderson, A. Domenech-Sanchez, J. W. Biddle, C. D. Steward, S. Alberti, K. Bush, and F. C. Tenover. 2001. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45:1151-1161.[Abstract/Free Full Text]
    13. 13
  13. Zavascki, A. P., L. Z. Goldani, J. Li, and R. L. Nation. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60:1206-1215.[Abstract/Free Full Text]
Jooyun Lee*
Gopi Patel
Shirish Huprikar
David P. Calfee
Division of Infectious Diseases, Department of Medicine

Stephen G. Jenkins
Department of Pathology
Mount Sinai School of Medicine
One Gustave L. Levy Place
New York, New York 10029

* Phone: (212) 241-6741 Fax: (212) 534-3240 Email: jooyun.lee{at}mssm.edu

Journal of Clinical Microbiology, May 2009, p. 1611-1612, Vol. 47, No. 5
0095-1137/09/$08.00+0     doi:10.1128/JCM.02466-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Endimiani, A., Hujer, K. M., Hujer, A. M., Armstrong, E. S., Choudhary, Y., Aggen, J. B., Bonomo, R. A. (2009). ACHN-490, a Neoglycoside with Potent In Vitro Activity against Multidrug-Resistant Klebsiella pneumoniae Isolates. Antimicrob. Agents Chemother. 53: 4504-4507 [Abstract] [Full Text]  
  • Zavascki, A. P., Li, J., Nation, R. L., Superti, S. V., Barth, A. L., Lutz, L., Ramos, F., Boniatti, M. M., Goldani, L. Z. (2009). Stable Polymyxin B Susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite Persistent Recovery of These Organisms from Respiratory Secretions of Patients with Ventilator-Associated Pneumonia Treated with This Drug. J. Clin. Microbiol. 47: 3064-3065 [Full Text]  

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, J.
Right arrow Articles by Jenkins, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, J.
Right arrow Articles by Jenkins, S. G.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»